See analyst estimates and all valuation multiples for Vaccines & Immunotherapies
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $242B | 3.7x | 8.3x | |
| $189B | 3.0x | 7.6x | |
| $125B | 2.4x | 8.1x | |
| $105B | 2.5x | 7.4x | |
| $75.9B | 4.8x | 14.2x | |
| $57.3B | 7.1x | 24.3x | |
| $9.7B | n/a | n/a | |
| $8.7B | 4.3x | 64.4x | |
| $8.6B | 3.3x | -6.0x | |
| $7.3B | 7.8x | 26.9x | |
| $6.0B | 2.8x | -1.6x | |
| $5.0B | 11.3x | 35.8x | |
| $4.1B | n/a | n/a | |
| $3.8B | 5.7x | 15.1x | |
| $3.8B | 11.9x | 75.3x | |
| $2.9B | 6.6x | 21.8x | |
| $2.6B | 29.2x | n/a | |
| $2.6B | 2.7x | 7.7x | |
| $2.6B | n/a | n/a | |
| $2.4B | 8546.5x | n/a | |
| $2.3B | 6.2x | 22.8x | |
| $2.3B | 11.0x | -57.9x | |
| $2.0B | 5.4x | -34.4x | |
| $1.5B | n/a | n/a | |
| $1.4B | 7.6x | 25.1x | |
| $1.3B | 7.0x | 17.4x | |
| $1.3B | 7.4x | 24.9x | |
| $1.3B | 9.3x | 15.7x | |
| $1.2B | 38.5x | -40.5x | |
| $1.2B | 7.5x | 8.3x | |
| $1.2B | n/a | n/a | |
| $1.2B | 275.3x | -4.8x | |
| $969M | 1.0x | 3.2x | |
| $955M | 6.1x | 11.8x | |
| $954M | 17.5x | -9.5x | |
| $948M | 109.6x | -4.4x | |
| $940M | 4.5x | -30.8x | |
| $886M | 3.8x | 12.1x | |
| $840M | 2.6x | 53.1x | |
| $828M | 4.5x | n/a | |
| $795M | 4.3x | -14.9x | |
| $752M | 3.2x | -2.0x | |
| $726M | 9.5x | -4.7x | |
| $666M | 254.8x | -4.7x | |
| $636M | 3371.2x | n/a | |
| $627M | 5.4x | -5.9x | |
| $608M | 229.5x | -31.0x | |
| $578M | n/a | n/a | |
| $566M | 6.9x | -25.1x | |
| $564M | n/a | n/a | |
| $540M | 140.8x | n/a | |
| $528M | n/a | -8.4x | |
| $461M | 2.1x | n/a | |
| $443M | 729.6x | n/a | |
| $435M | n/a | n/a | |
| $403M | 3.9x | 17.8x | |
| $388M | n/a | n/a | |
| $364M | 18.4x | -1237.4x | |
| $346M | 1.9x | 8.1x | |
| $345M | 7.7x | -4.4x | |
| $302M | 12.0x | -0.6x | |
| $291M | n/a | n/a | |
| $278M | 314621.8x | -10.8x | |
| $276M | 1.3x | 6.8x | |
| $247M | n/a | -6.1x | |
| $207M | 1.2x | n/a | |
| $207M | 5.7x | -18.0x | |
| $206M | 19.7x | n/a | |
| $183M | n/a | n/a | |
| $166M | n/a | n/a | |
| $166M | n/a | n/a | |
| $165M | 95434.4x | -6.6x | |
| $159M | 2.7x | 10.3x | |
| $156M | n/a | n/a | |
| $142M | n/a | n/a | |
| $139M | n/a | n/a | |
| $134M | 34.1x | -7.9x | |
| $127M | n/a | n/a | |
| $126M | n/a | n/a | |
| $124M | n/a | n/a | |
| $123M | n/a | n/a | |
| $114M | n/a | n/a | |
| $112M | n/a | -3.7x | |
| $99.7M | 891.8x | n/a | |
| $95.9M | 0.8x | 7.5x | |
| $95.4M | 9.6x | n/a | |
| $87.0M | 3950.6x | -0.4x | |
| $83.4M | 8.0x | n/a | |
| $81.0M | n/a | -0.5x | |
| $79.0M | 10384.3x | -0.3x | |
| $74.5M | n/a | n/a | |
| $72.0M | n/a | -3.2x | |
| $71.8M | 17.5x | n/a | |
| $71.6M | 1.2x | -1.2x | |
| $67.1M | n/a | n/a | |
| $60.9M | 6.3x | n/a | |
| $57.3M | n/a | n/a | |
| $52.1M | 0.8x | -0.2x | |
| $47.1M | 5.8x | -0.3x | |
| $43.0M | n/a | n/a | |
| $42.4M | n/a | -0.3x | |
| $41.4M | 494.7x | n/a | |
| $41.3M | 5.3x | n/a | |
| $40.6M | 32.8x | -0.6x | |
| $38.6M | 19.7x | n/a | |
| $38.3M | n/a | n/a | |
| $35.9M | 12.6x | -1.2x | |
| $34.1M | 82.0x | n/a | |
| $31.2M | n/a | -0.8x | |
| $26.6M | 9.4x | -0.1x | |
| $26.0M | n/a | n/a | |
| $24.5M | 58.9x | n/a | |
| $24.2M | n/a | n/a | |
| $19.8M | 14.6x | -1.4x | |
| $18.5M | n/a | -0.2x | |
| $18.1M | n/a | n/a | |
| $16.6M | n/a | -0.2x | |
| $16.5M | 391.5x | n/a | |
| $15.1M | 5.4x | n/a | |
| $13.1M | 5.1x | n/a | |
| $12.9M | n/a | n/a | |
| $8.9M | n/a | n/a | |
| $6.1M | 1.4x | n/a | |
| $4.1M | 0.5x | -0.0x | |
| $2.6M | 0.7x | -0.2x | |
| $1.5M | 0.7x | -0.0x | |
| $0.5M | 0.1x | n/a | |
| -$2.5M | -0.0x | 0.0x | |
| -$12.8M | n/a | n/a | |
| -$18.7M | -5.8x | n/a | |
| -$32.4M | -0.3x | n/a | |
| -$36.1M | n/a | 0.3x | |
| -$57.7M | n/a | n/a | |
| -$60.5M | -1113.7x | n/a | |
| -$72.8M | -2.3x | n/a | |
| -$85.0M | n/a | n/a |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Vaccines & Immunotherapies